Real World Evidence Evidence & Data Partnerships

Oct 14, 2014 - Oct 15, 2014, Bethesda

This year real patient data will change healthcare.

Real World Data: A Bigger Piece of the Pharma Picture

Experts and analysts worldwide are increasingly citing the advantages of shifting data collection methods in the pharma industry to yield research-based evidence.



According to an article in Forbes pharmaceutical customers and regulators are zealous in combing real world data for any insights that can drive down cost and protect patient safety. It is believed that a full-sized analysis of this form of data might lay the foundation of value-based pricing methods that could redefine the basis of access and competition.

ANTICIPATED OUTCOMES

At present real world data presents pharmaceutical companies the opportunity to characterise diseases and populations, develop new products and therapies, assess products and therapies already in use and target products and services by identifying underserved patient populations, high cost areas for risk-based product pricing and sub-populations with superior product response.

Association of the British Pharmaceutical Industry’s chief executive Stephen Whitehead said, “The conduct of real world studies presents a unique proposition to encourage the investment, innovation and the use of skills brought by the pharmaceutical industry in the UK. It maximises the use of resources, benefits patients and their compliance with taking their medicines, and facilitates collaboration between the pharmaceutical industry, researchers and clinicians.”

“The collection and use of real world data will potentially lead to a better understanding of conditions and treatments in a wider population. This will deliver benefits such as patients suffering fewer side effects, better management of chronic conditions and the avoidance of preventable hospitalisations. Real world data will provide us with the means for assessing the true value of a medicine – it will provide us with the opportunity to improve patient quality of life while reducing NHS costs.”

EXPECTED CHALLENGES

Pfizer’s Worldwide Medical and Outcomes Research Senior Director Andreas M. Pleil (PhD) has however identified limitations in the real world data approach, illustrating factors such as bias in treatment decisions leading to differences in outcomes, the lack of “scientific rigor” and the plain fact that it is costly to conduct.

PharmaTimes Katrina Megget reported suggestions (noting the challenges in the current research environment that will need to be overcome) that include a means for UK pharma companies to present the case to their global colleagues, encouraging NHS partnership with the industry and pushing for the use of electronic health records as a basis for research proficiencies.

THE RESULTS MAY VARY

By comparing and contrasting the sources, a pattern emerges which declares successful RWD strategies can shift or protect whole market opportunities, where they can determine whether or not product goes ahead.  How much these strategies deliver will vary, but what is clear is that the move toward RWD availability has begun.   

On that basis alone, trends and patterns within the global pharmaceutical arena will ultimately emerge during 2013, which promise to demonstrate the merit in adhering to the real world data approach, or will at least explain if the approach is working.



Real World Evidence Evidence & Data Partnerships

Oct 14, 2014 - Oct 15, 2014, Bethesda

This year real patient data will change healthcare.